Abstract 141P
Background
To investigate the correlation between different expression of CDK5RAP3 and UFM1 and the long-term survival of patients undergoing radical gastrectomy.
Methods
The expression of CDK5RAP3 and UFM1 in cancer and adjacent tissues of gastric cancer patients were detected, and their relationship with clinical pathological parameters and long-term prognosis were analyzed.
Results
Low expression of CDK5RAP3 was detected in 102 patients (78.5%), and UFM1 expression was low in 99 patients (76.2%), and the expression of the two was significantly positively correlated. Based on the co-expression of CDK5RAP3 and UFM1, we found that the low expression of CDK5RAP3 and UFM1 was closely related to the depth of invasion (P = 0.041), lymph node metastasis (p = 0.006), and TNM stage (P = 0.000). In Kaplan-Meier analysis, the prognosis of patients with low expression of CDK5RAP3 and UFM1 was significantly poorer than that of patients with high expression of CDK5RAP3 or UFM1 (p = 0.005), and could be used as an independent risk factor for the prognosis of the entire group of patients. The co-expression of CDK5RAP3 and UFM1 had the largest area under the ROC curve, and the patients’ long-term prognosis was better than the TNM stage alone, and has statistical significance (p <0.05).
Conclusions
The expressions of CDK5RAP3 and UFM1 are significantly reduced in gastric cancer tissues. The co-expression of CDK5RAP3 and UFM1 is an independent prognostic factor for gastric cancer. Combining the expression of the two can provide a more accurate prognostic model for predicting the overall survival of gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
77P - Dual targeting oxidative phosphorylation and glycolysis in triple-negative breast cancers: En route to effective inhibition of tumour metabolism
Presenter: Alexander Scherbakov
Session: e-Poster Display Session
78P - Novel allogeneic cell immunotherapy for advanced cancers
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
86P - The impact of sarcopenia on chemotherapy toxicity and survival rate among colorectal cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Timotius Hariyanto
Session: e-Poster Display Session
87P - Predictive risk factors and online nomograms for colon cancer with synchronous liver metastasis
Presenter: Yajuan Zhu
Session: e-Poster Display Session
88P - Research of radiomics based on indeterminate lung nodules predicting prognosis of LARC patients
Presenter: Zhang Zhiyuan
Session: e-Poster Display Session
89P - Biomarker analysis of regorafenib dose escalation study (RECC study): A phase II multicenter clinical trial in Japan
Presenter: Masanobu Enomoto
Session: e-Poster Display Session
90P - The role of miR-133a-3p/SP1/IGF1R axis in the progression of colorectal cancer
Presenter: Hui Li
Session: e-Poster Display Session
91P - Prognostic biomarker of clinical outcome in locally advanced rectal cancer in Chinese patients
Presenter: Sandy Ho
Session: e-Poster Display Session
92P - Development and validation of risk and prognostic nomograms for bone metastases in advanced colorectal cancer patients
Presenter: Nan Wang
Session: e-Poster Display Session
93P - Assessment of nutritional status of colorectal cancer patients in a tertiary government hospital
Presenter: Rogelio Velasco
Session: e-Poster Display Session